Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2011 pubmed 6 citations

Expression of a novel dual-functional protein--the antimicrobial peptide LL-37 fused with human acidic fibroblast growth factor in Escherichia coli.

Shen. Juan J; Lu. Xue-Mei XM; Jin. Xiao-Bao XB; Ding. Jing J; Li. Xiao-Bo XB; Mei. Han-Fang HF; Chu. Fu-Jiang FJ; Zhu. Jia-Yong JY

Key Findings

  • A fusion protein (LL‑37‑haFGF) was successfully produced in E. coli and purified to >95% purity.
  • The hybrid showed stronger antimicrobial activity in vitro than LL‑37 alone.
  • The hybrid also promoted cell proliferation in NIH 3T3 fibroblast cells, indicating mitogenic (healing) potential.

Practical Outcomes

  • For DIY biohackers, the study shows that combining an antimicrobial peptide with a growth factor can boost both infection control and tissue repair, but the work is still at the laboratory stage. Producing or obtaining this specific fusion protein isn’t currently feasible for personal use, so the immediate takeaway is limited to informing future peptide design rather than offering a ready‑to‑use protocol.

Summary

Scientists made a new protein that joins the natural antimicrobial peptide LL‑37 with a growth factor that helps skin cells heal. In lab tests, this hybrid was better at killing microbes and also helped mouse fibroblast cells grow, suggesting it could be useful for faster wound healing.

Abstract

Human acidic fibroblast growth factor (haFGF) stimulates repair of delayed healing which still remains a tremendously world-wide issue. However, most of the patients with delayed healings have to face another creeping problem - microbial infection, which is one of the most frequent complications that still lead to wound healing failure. LL-37/hCAP-18 is the only cathelicidin-derived antimicrobial peptide found in human with a wide range of antimicrobial activities. In the present study, a novel hybrid protein combining LL-37 with haFGF was designed. The DNA sequence encoding recombination fusion protein LL-37-haFGF was subcloned into the pET-21b vector for protein expression in Escherichia coli strain BL21 (DE3). The recombinant protein was expressed as a His-tagged protein and purified using a combination of Ni affinity and CM-Sepharose chromatography at a purity of 95.43% as detected by RP-HPLC and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Antimicrobial activity assays showed that the purified LL-37-haFGF had improved antimicrobial activities in vitro compared with LL-37. Methylthiazoletetrazolium (MTT) assay showed that the purified LL-37-haFGF also had a distinct mitogenic activity in NIH 3T3 cells. These data suggests the recombinant protein LL-37-haFGF has pharmaceutical potential for applications in wound healing.

Study Information

Provider

pubmed

Year

2011

Date

2011-09-22T00:00:00.000Z

DOI

10.1016/j.pep.2011.09.007

Citations

6

References

39